What is the revenue and EPS growth rate for Bionano Genomics year over year?

What is Bionano Genomics's gross profit margin?

What guidance did Bionano Genomics's management provide for the next earnings period?

What is Bionano Genomics's latest dividend and current dividend yield?

What does Bionano Genomics do and what are its main business segments?

Did Bionano Genomics beat or miss consensus estimates last quarter?

What were the key takeaways from Bionano Genomics’s earnings call?

What is the market's earnings forecast for Bionano Genomics next quarter?

- **Revenue Growth**: Q3 2025 revenue up 21% YoY to $7.4M. Core business momentum with 12% YoY growth in recurring consumables. 
- **Profitability Expansion**: 46% gross margin (vs 26% prior year) and 40% opex reduction. 
- **Strategic Focus**: Shifting to a high-margin, predictable model with routine users. 
- **Market Expansion**: Japanese market potential and reimbursement progress. 
- **Financial Discipline**: $31.8M cash runway. 
- **Growth Drivers**: 7% YoY flow cell growth and 15% consumables revenue expansion.

**【CEO Summary Section】**
- Q3 2025 revenue reached $7.4 million, up 21% YoY. Core revenue (excluding discontinued services) grew 12% YoY. Flow cell sales hit a record 8,390 units (+7% YoY), driven by routine user utilization. Non-GAAP gross margin improved to 46% from 26% in Q3 2024. Operating expenses decreased 40% YoY to $9.7 million. The company reiterates 2025 full-year revenue guidance of $26-30 million.

**【CFO Financial Commentary】**
- Strong cash position of $31.8 million post $10M equity raise. Non-GAAP metrics show improved profitability: 46% gross margin (vs 22% in Q1 2023) and 72% product mix from consumables/software (vs 62% in 2024). The company targets maintaining flat operating expenses while investing strategically.

**【Q&A Highlights】**
- **Utilization Targets**: CEO expects routine users to move from 4-40 samples/week to a mid-range target of ~20 samples/week. 
- **Japanese Market**: 1 installed system serving academic and pharma customers. Growth potential in cell therapy applications. 
- **Reimbursement Progress**: New CPT code pricing at $1,263.53, higher than legacy microarray codes. 97 new OGM publications in Q3 (+10% YoY).

Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

BNGO

BNGO fundamentals

You can ask Aime